Brief: Ascletis Announces First Participants Dosed In A U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, And Semaglutide For The Treatment Of Obesity
20/05/2025 12:07
May 20 (Reuters) - Ascletis Pharma Inc 1672.HK: ASCLETIS ANNOUNCES FIRST PARTICIPANTS DOSED IN A U.S. CLINICAL STUDY COMBINING ADIPOSE-TARGETED, ONCE-MONTHLY INJECTABLE SMALL MOLECULE THRΒ AGONIST, ASC47, AND SEMAGLUTIDE FOR THE TREATMENT OF OBESITY ASCLETIS PHARMA INC - TOPLINE DATA FROM STUDY EXPECTED IN Q4 2025 Source text: ID:nPn60D9v5a Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management